Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, a new treatment
called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is
called a phase II study.
Axitinib is an oral medication that can interfere with cancer cell growth and reduce the
growth of blood vessels around tumors. This study will help find out if axitinib is a useful
drug for treating patients with adenoid cystic carcinomas. Axitinib is an experimental drug
that has not yet been approved by the Food and Drug Administration for use in adenoid cystic
carcinoma.